Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
12.03. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 12.03.2025 | 642 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 12.03.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 12.03.2025ISIN NameCA3719571018 GENESIS... ► Artikel lesen | |
12.03. | BenevolentAI: Result of Extraordinary General Meeting and Delisting from Euronext Amsterdam | 357 | Business Wire | Regulatory News:
BenevolentAI, ("BenevolentAI" or "the Company") (Euronext Amsterdam: BAI), a pioneer in AI-driven drug discovery, today announces that:
All resolutions proposed at its Extraordinary... ► Artikel lesen | |
12.03. | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.03.2025 | 491 | Xetra Newsboard | Das Instrument 4W7 CA78412Y2024 SBD CAPITAL CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 12.03.2025 und ex Kapitalmassnahme am 13.03.2025 The instrument 4W7 CA78412Y2024 SBD CAPITAL CORP. EQUITY... ► Artikel lesen | |
06.02. | Proposed Delisting via Merger of BenevolentAI into Osaka Holdings S.à r.l. and Publication of Notice of Extraordinary General Meeting | 662 | Business Wire | Regulatory News:
BenevolentAI, ("BenevolentAI" or "the Company") (Euronext Amsterdam: BAI), a pioneer in AI-driven drug discovery, today announces:
Subject to shareholder approval, the proposed... ► Artikel lesen | |
11.12.24 | AI Biotech BenevolentAI Restructures Again, This Time to Return to Its TechBio Roots | 12 | MedCity News | ||
BENEVOLENTAI Aktie jetzt für 0€ handeln | |||||
11.12.24 | BenevolentAI restructures; Lilly preps $15B buyback program | 11 | BioPharma Dive | ||
11.12.24 | Mulvany hits the reset button at BenevolentAI | 12 | pharmaphorum | ||
11.12.24 | BenevolentAI pivots back to 'TechBio' roots, causing more layoffs | 11 | FierceBiotech | ||
11.12.24 | BenevolentAI Unveils Major Strategic Overhaul With Return to Original Mission | 353 | Business Wire | Changes mark a return to BenevolentAI's foundational strengths Initiates significant organisational restructuring Announces intention to evaluate delisting from Euronext Amsterdam
Regulatory... ► Artikel lesen | |
17.10.24 | BenevolentAI Appoints Kenneth Mulvany as Executive Chairman | 287 | Business Wire | Founder of leading AI drug discovery company returns to the executive management team to capitalise on the growing adoption of AI in drug discovery and development
BenevolentAI ("BenevolentAI"... ► Artikel lesen | |
10.10.24 | BenevolentAI to Present on Explainable AI for Drug Discovery at BioTechX Europe 2024 | 338 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that Dr James Malone, Chief Technology... ► Artikel lesen | |
19.09.24 | BenevolentAI Interim Results for the Six Months Ended 30 June 2024 | 428 | Business Wire | Strengthened Executive Leadership and Board Positive Top Line Phase I Data Reported for BEN-8744, Full Data to be Presented at Upcoming Leading Medical Conference Advancements in Target Identification... ► Artikel lesen | |
06.09.24 | BenevolentAI Notice of Interim Results | 415 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, will announce its interim results for the six months... ► Artikel lesen | |
04.07.24 | BenevolentAI: Appointment of Adviser | 410 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the... ► Artikel lesen | |
03.07.24 | BenevolentAI: Leadership Team Change | 477 | Business Wire | Regulatory News:
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced artificial intelligence (AI) to accelerate biopharma drug discovery, today... ► Artikel lesen | |
25.06.24 | BenevolentAI and AstraZeneca Collaboration Yields Continued Success as Further Novel Target Progressed Into Portfolio | 929 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that AstraZeneca has added a novel target... ► Artikel lesen | |
19.06.24 | BenevolentAI CEO to Join Panel at Morgan Stanley 3rd Annual Life Sciences AI Summit | 403 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces that it will participate in the upcoming... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
RECURSION PHARMACEUTICALS | 5,050 | +10,38 % | Recursion Pharmaceuticals: MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy | ||
ABCELLERA BIOLOGICS | 2,135 | +3,24 % | Why AbCellera Biologics Stock Raced Nearly 6% Higher Today | ||
ANAVEX LIFE SCIENCES | 6,900 | +1,62 % | Anavex Life Sciences Corp. Q2 Loss Beats Estimates | WASHINGTON (dpa-AFX) - Anavex Life Sciences Corp. (AVXL) released Loss for second quarter that beat the Street estimates.The company's earnings came in at -$11.20 million, or -$0.13 per share.... ► Artikel lesen | |
VERACYTE | 24,000 | +1,69 % | Cathie Wood's ARK sells Palantir and Roblox, buys Veracyte and Guardant | ||
ASCLETIS PHARMA | 0,830 | +1,22 % | Sagimet Biosciences Inc.: Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis | Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was well tolerated Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to... ► Artikel lesen | |
VERVE THERAPEUTICS | 6,080 | +6,20 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on May 30, 2025... ► Artikel lesen | |
BIOMEA FUSION | 2,540 | +4,53 % | Biomea Fusion, Inc.: Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights | Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patients... ► Artikel lesen | |
RELAY THERAPEUTICS | 3,360 | +4,02 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025 | Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer Data continue to support... ► Artikel lesen | |
JASPER THERAPEUTICS | 5,680 | 0,00 % | Jasper Therapeutics, Inc.: Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress | ||
ABSCI | 2,960 | +4,23 % | Absci Corporation: Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease | Absci becomes clinical stage company with ABS-101, first AI-designed biologic for IBD, beginning Phase 1 trial Preclinical data for ABS-101 demonstrates high potency and potential for quarterly dosing... ► Artikel lesen | |
LANTERN PHARMA | 3,430 | 0,00 % | Lantern Pharma's LP-184 shows promise for pediatric brain cancer | ||
Y-MABS THERAPEUTICS | 5,270 | +3,33 % | Y-mAbs Therapeutics, Inc.: Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments | Reported Net Product Revenues of $20.9 million for the first quarter of 2025, a year-over-year increase of approximately 8% National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines... ► Artikel lesen | |
QIAGEN | 40,185 | -0,24 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
BIONTECH | 96,50 | +0,26 % | Allianz gegen Krebs: BioNTech sichert sich Milliarden-Deal mit Bristol Myers: Aktie explodiert! | © Foto: picture alliance / Laci Perenyi | Laci PerenyiBioNTech erhält 1,5 Milliarden US-Dollar Vorschuss von Bristol Myers - für die gemeinsame Entwicklung eines vielversprechenden Krebswirkstoffs.... ► Artikel lesen | |
EVOTEC | 7,018 | +0,34 % | DAX nach Feiertag wieder bei 24.000 - Douglas, Evotec, Fresenius, Merck, Renk und SAP im Check | An Christi Himmelfahrt hat es am deutschen Aktienmarkt bei dünnen Umsätzen etwas an Boden verloren. Die Verluste macht der DAX aber am letzten Handelstag im Mai schon wieder gut, wobei die Zollpolitik... ► Artikel lesen |